Advanced Imaging-Guided CRT for Heart Failure
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a mechanistic clinical trial with randomization to guidance for the CRT procedure using cardiac magnetic resonance (CMR) and computed tomography angiography (CTA) versus a standard procedure.
Who Is on the Research Team?
Kenneth Bilchick, MD
Principal Investigator
University of Virginia Health System
Are You a Good Fit for This Trial?
This trial is for individuals with chronic systolic heart failure, having a left ventricular ejection fraction (LVEF) of 35% or less, and who meet the criteria for Cardiac Resynchronization Therapy (CRT). Participants must be able to consent. Those with metal in their body, severe claustrophobia, kidney issues, liver transplant, gadolinium allergy or significant irregular heartbeat are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Patients undergo CMR, CTA, echocardiography, blood testing, cardiopulmonary exercise testing, and complete a heart failure questionnaire
Treatment
Patients receive CRT with either standard procedure or CMR-guided LV lead placement
Follow-up
Participants are monitored for safety and effectiveness after treatment with assessments at 6 and 12 months
Long-term Follow-up
Clinical follow-up for survival free of appropriate ICD therapies over 3 years
What Are the Treatments Tested in This Trial?
Interventions
- CMR/CTA Guidance for CRT
CMR/CTA Guidance for CRT is already approved in European Union, United States for the following indications:
- Heart failure with reduced ejection fraction (HFrEF)
- Left bundle branch block (LBBB)
- QRS duration ≥150 ms
- Symptomatic heart failure with reduced ejection fraction (HFrEF)
- Left bundle branch block (LBBB)
- QRS duration ≥150 ms
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Virginia
Lead Sponsor